Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.

The predefined primary end point of this study did not reach statistical significance, and arguably this was because of persistence of symptomatic improvement during the withdrawal phase even in the placebo group; this unanticipated carryover effect reduced the power of the study design.

also in 111,027 other papers